Insider Buying: ANI Pharmaceuticals Inc (ANIP) Director Purchases 2,500 Shares of Stock

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Director Thomas Haughey acquired 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The shares were purchased at an average cost of $69.30 per share, for a total transaction of $173,250.00. Following the acquisition, the director now owns 6,291 shares in the company, valued at $435,966.30. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

NASDAQ ANIP opened at $70.38 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.67 and a current ratio of 0.92. ANI Pharmaceuticals Inc has a twelve month low of $36.92 and a twelve month high of $74.00. The firm has a market cap of $819.38 million, a P/E ratio of 15.27 and a beta of 2.37.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.25. ANI Pharmaceuticals had a return on equity of 28.63% and a net margin of 6.58%. The company had revenue of $52.90 million for the quarter, compared to the consensus estimate of $50.57 million. During the same quarter last year, the business posted $1.32 EPS. ANI Pharmaceuticals’s revenue for the quarter was up 13.8% on a year-over-year basis. On average, analysts forecast that ANI Pharmaceuticals Inc will post 5.79 earnings per share for the current fiscal year.

Several equities research analysts recently weighed in on ANIP shares. ValuEngine raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, February 4th. BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, February 14th. Raymond James set a $73.00 price objective on ANI Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, February 28th. TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 19th. Finally, Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $76.00 price objective on the stock in a report on Thursday, March 28th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $84.50.

Large investors have recently made changes to their positions in the stock. Financial Gravity Wealth Inc. bought a new position in ANI Pharmaceuticals during the 1st quarter worth $54,000. Quantamental Technologies LLC raised its position in ANI Pharmaceuticals by 169.4% during the 1st quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock worth $61,000 after purchasing an additional 542 shares during the last quarter. South Dakota Investment Council bought a new position in ANI Pharmaceuticals during the 4th quarter worth $45,000. BNP Paribas Arbitrage SA raised its position in ANI Pharmaceuticals by 55,466.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock worth $118,000 after purchasing an additional 1,664 shares during the last quarter. Finally, Truvestments Capital LLC bought a new position in ANI Pharmaceuticals during the 1st quarter worth $140,000. 60.02% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was first published by Stock Observer and is owned by of Stock Observer. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.thestockobserver.com/2019/05/17/insider-buying-ani-pharmaceuticals-inc-anip-director-purchases-2500-shares-of-stock.html.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Read More: Reverse Stock Split

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.